NeuroMetrix Launches New Website to Support Growth of Quell Wearable Pain Relief Technology

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the launch of a new website to promote Quell^®, the company's rapidly growing pain relief brand.

The new site reflects NeuroMetrix' focus on helping people with chronic pain reclaim their lives. The QuellRelief.com website incorporates user-requested content such as:

• Compelling testimonials of the real-world experiences of chronic pain sufferers using Quell technology
• Enhanced clinical and scientific data for healthcare professionals
• Improved content to support current Quell users
• A retail finder to help locate one of the 1,500 stores or online outlets selling Quell

"With over 100,000 visits to QuellRelief.com each month, we designed the new site with the user experience in mind," said Frank McGillin, Senior Vice President and General Manager, Consumer. "We've made it easier to explore the facts around chronic pain and how Quell technology may help."

About Quell Wearable Pain Relief Technology

Quell is FDA cleared and designed for the millions of people suffering from chronic pain. The advanced wearable technology delivers 100% drug free relief and is available without a prescription. Quell can be used during the day while active and at night while sleeping. Quell gives users the option to start, stop, and adjust therapy discreetly via their smartphone. It also provides therapy utilization and advanced sleep tracking. Quell is available at select healthcare professionals and retailers. To find a Quell retailer, visit the Store Locator at QuellRelief.com.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck^®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005393/en/

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media